Breaking News
16 hours ago
Simantini Singh Deo

Idorsia secures up to CHF 250M from Pharmakon Advisors, retiring a May 2027 debt maturity and extending cash runway into 2028.
Simantini Singh Deo

Ultomiris hits 43.4% UPCR reduction at 34 weeks in Phase III IgA nephropathy trial, signalling a potential new indication filing with FDA and EMA.
Simantini Singh Deo

Eli Lilly's oral GLP-1 candidate shows fat loss across menopause stages in Phase 3 ATTAIN trials, raising scale-up and formulation questions.
Simantini Singh Deo

Lupin partners with Laboratorios ERN to commercialise Luforbec in Spain, combining inhaler manufacturing depth with local distribution reach.
Simantini Singh Deo
